ATE550030T1 - Neue verwendung von antisekretorischem faktor - Google Patents

Neue verwendung von antisekretorischem faktor

Info

Publication number
ATE550030T1
ATE550030T1 AT04775470T AT04775470T ATE550030T1 AT E550030 T1 ATE550030 T1 AT E550030T1 AT 04775470 T AT04775470 T AT 04775470T AT 04775470 T AT04775470 T AT 04775470T AT E550030 T1 ATE550030 T1 AT E550030T1
Authority
AT
Austria
Prior art keywords
cell
condition
stem cell
disease
antisecretoric
Prior art date
Application number
AT04775470T
Other languages
English (en)
Inventor
Hans-Arne Hansson
Eva Jennische
Stefan Lange
Ivar Loennroth
Peter Eriksson
Anders Persson
Original Assignee
Faktor Ab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faktor Ab As filed Critical Faktor Ab As
Application granted granted Critical
Publication of ATE550030T1 publication Critical patent/ATE550030T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
AT04775470T 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor ATE550030T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0322645.3A GB0322645D0 (en) 2003-09-26 2003-09-26 Use of antisecretory factor peptides
PCT/SE2004/001369 WO2005030246A1 (en) 2003-09-26 2004-09-24 Novel use of antisecretory factor

Publications (1)

Publication Number Publication Date
ATE550030T1 true ATE550030T1 (de) 2012-04-15

Family

ID=29286947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775470T ATE550030T1 (de) 2003-09-26 2004-09-24 Neue verwendung von antisekretorischem faktor

Country Status (18)

Country Link
US (2) US20070009575A1 (de)
EP (1) EP1734989B1 (de)
JP (1) JP4943847B2 (de)
KR (1) KR101159858B1 (de)
CN (2) CN1856320A (de)
AT (1) ATE550030T1 (de)
AU (1) AU2004275682B2 (de)
BR (1) BRPI0414793A (de)
CA (1) CA2537335C (de)
DK (1) DK1734989T3 (de)
ES (1) ES2384385T3 (de)
GB (1) GB0322645D0 (de)
IL (1) IL174464A (de)
NO (1) NO340187B1 (de)
NZ (1) NZ545661A (de)
RU (1) RU2416426C2 (de)
WO (1) WO2005030246A1 (de)
ZA (1) ZA200601807B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008013777A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
AU2012201165B2 (en) * 2006-04-27 2013-12-19 Lantmannen As-Faktor Ab New approach to treat intraocular hypertension
KR101757523B1 (ko) * 2006-04-27 2017-07-12 란트만넨 아스-팍토르 아베 구획 증후군의 치료에 사용하기 위한 항분비 단백질
MX2008013769A (es) * 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Uso de factores antisecretores para el tratamiento de hipertension intraocular.
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
ITMI20120008A1 (it) * 2012-01-04 2013-07-05 Biava Maura Composizioni ad attività anti-neurodegenerativa
US9738553B2 (en) * 2012-03-16 2017-08-22 Aquatech International, Llc Process for purification of produced water
CN104540952A (zh) * 2012-05-18 2015-04-22 衣阿华大学研究基金会 用于治疗淀粉状蛋白沉积的方法和组合物
EP2934564B1 (de) * 2012-12-20 2018-05-23 Lantmännen AS-Faktor AB Antisekretorischem faktor (af) zur verwendung in der behandlung von glioblastom
US11253552B2 (en) 2015-07-10 2022-02-22 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of AF-16
US11407796B2 (en) 2016-07-18 2022-08-09 Lantmännen As-Faktor Ab Antisecretory factor 17
JP7217760B2 (ja) 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および／または予防の使用のための抗分泌因子
CN112770643A (zh) 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化脱壳燕麦的可消耗产品
EP3855935A1 (de) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB Verbrauchsprodukt mit weizenmalz
AU2021243735A1 (en) * 2020-03-26 2022-10-13 Lantmännen Functional Foods Ab A consumable product comprising malted cereals for promoting recovery at physical activity
CN112006035B (zh) * 2020-07-24 2021-07-30 江西新龙生物科技股份有限公司 用于防治植物病害的微生物源杀菌剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566455B1 (en) * 1995-06-07 2009-07-28 Gpc Biotech, Inc. E6AP-binding proteins
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
CA2340721A1 (en) * 1999-06-21 2001-01-25 George Tuszynski Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
WO2002055695A1 (fr) * 2001-01-09 2002-07-18 Keio University Antigene de gliomes humains et procede de preparation de cet antigene
WO2003063688A2 (en) * 2002-01-25 2003-08-07 Incyte Corporation Protein modification and maintenance molecules

Also Published As

Publication number Publication date
US20070009575A1 (en) 2007-01-11
RU2006114030A (ru) 2007-11-20
CN1856320A (zh) 2006-11-01
JP4943847B2 (ja) 2012-05-30
AU2004275682A1 (en) 2005-04-07
NO20060901L (no) 2006-06-20
US8748367B2 (en) 2014-06-10
WO2005030246A1 (en) 2005-04-07
KR20060097718A (ko) 2006-09-14
DK1734989T3 (da) 2012-07-09
GB0322645D0 (en) 2003-10-29
NO340187B1 (no) 2017-03-20
US20100286052A1 (en) 2010-11-11
CN103028110B (zh) 2016-02-17
CA2537335A1 (en) 2005-04-07
EP1734989B1 (de) 2012-03-21
BRPI0414793A (pt) 2006-11-21
IL174464A0 (en) 2006-08-01
JP2007506735A (ja) 2007-03-22
RU2416426C2 (ru) 2011-04-20
CN103028110A (zh) 2013-04-10
AU2004275682B2 (en) 2010-01-28
EP1734989A1 (de) 2006-12-27
IL174464A (en) 2015-08-31
NZ545661A (en) 2009-10-30
ZA200601807B (en) 2007-06-27
KR101159858B1 (ko) 2012-06-25
CA2537335C (en) 2017-12-05
ES2384385T3 (es) 2012-07-04

Similar Documents

Publication Publication Date Title
ATE550030T1 (de) Neue verwendung von antisekretorischem faktor
Schlender et al. Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro
Allocati et al. p63/p73 in the control of cell cycle and cell death
Zheng et al. Ginkgolide B promotes the proliferation and differentiation of neural stem cells following cerebral ischemia/reperfusion injury, both in vivo and in vitro
ATE139261T1 (de) Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
EP1059929A4 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
HUP0500477A2 (hu) Eljárások és készítmények embrionális és felnőttkori őssejtek támogatására stromasejtek alkalmazásával
DE69132352D1 (de) Protein-antagonisten der blut-koagulation und ihre verwendung
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
Jin et al. Amniotic epithelial cells promote wound healing in mice through high epithelialization and engraftment
ATE548049T1 (de) Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
WO2005046570A3 (en) Human stem cell materials and methods
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DE69930662D1 (de) Humane rezeptortyrosinkinase
Syu et al. Adipose-derived neural stem cells combined with acellular dermal matrix as a neural conduit enhances peripheral nerve repair
Mendes‐da‐Cruz et al. Neuropilins, semaphorins, and their role in thymocyte development
ATE322906T1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE602005018683D1 (de) Herstellung von 1,4-butandiol und/oder 2-methyl 1,3-propandiol
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE60239670D1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
Yu et al. Double‐stranded RNA induces melanocyte death via activation of Toll‐like receptor 3
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis